

Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 India T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



18th July 2024

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400001

National Stock Exchange of India, Exchange Plaza, 5<sup>th</sup> Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Scrip Code: BSE – AJANTPHARM 532331 | Scrip Code: NSE AJANTPHARM EQ

## Re: Regulation 30 - Proceedings of Annual General Meeting

Dear Sirs/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith summary of proceedings of 45<sup>th</sup> Annual General Meeting of the Company held on 18<sup>th</sup> July 2024 through Video- conference/Other Audio-Visual Means.

You are requested to kindly take above information on your records.

Thanking You,

Yours faithfully,

Gaurang Shah
Sr. VP – Legal and Company Secretary

Encl.: a/a

Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



## SUMMARY OF PROCEEDINGS OF 45<sup>TH</sup> ANNUAL GENERAL MEETING

45<sup>th</sup> Annual General Meeting (AGM) of the Members of the Company was held on 18<sup>th</sup> July 2024 through Video-conference/Other Audio-Visual Means (VC/OAVM). The meeting commenced at 11.00 a.m. and concluded at 11.37 a.m.

Mr. Mannalal Agrawal, Chairman of the Company, chaired the meeting.

All the Directors including Chairman of Audit Committee, Nomination and Remuneration Committee and Stakeholders' Relationship Committee were present at the meeting. The representatives of the Statutory Auditors and Secretarial Auditors were also present at the meeting.

Number of shareholders present in the meeting through Video-conference:

<b>Promoter and Promoter Group</b>	Public	Total
4	58	62

Company Secretary, Mr. Gaurang Shah, informed that the meeting was conducted through VC / OAVM in compliance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. He also gave general instructions regarding participation in the meeting.

Requisite quorum being present, the Chairman called the meeting to order. He welcomed members to the 45<sup>th</sup> AGM and requested the Managing Director to continue further proceedings.

Managing Director welcomed members to the 45<sup>th</sup> AGM and then other Directors, Statutory Auditor and Secretarial Auditor introduced themselves.

Managing Director then stated that Notice dated 2<sup>nd</sup> May 2024, convening the 45<sup>th</sup> AGM and annual report for the year ended 31<sup>st</sup> March 2024 were already circulated to the members electronically and with the permission of members the same were taken as read.

He mentioned that the audit reports of Statutory Auditors and Secretarial Auditors for the financial year 2023-2024, did not contain any qualifications or adverse remarks.

Managing Director then gave brief speech on performance of the Company and other important developments during the Financial Year 2023-2024.

Thereafter, following items of business as set out in the Notice of AGM, were tabled at the meeting for consideration of members and Managing Director invited speakers who had registered their names, for raising their queries and views on these items and the annual report.



Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 India

T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



#	Particulars	<b>Resolution required</b>
1.	Adoption of Consolidated and Standalone Financial	Ordinary Resolution
	Statements for the year ended 31st March 2024	
2.	Confirm interim dividend as final dividend	Ordinary Resolution
3.	Approve re-appointment of Mr. Mannalal B. Agrawal,	Ordinary Resolution
	retiring by rotation	
4.	Approve appointment of Mr. David Rasquinha as an	Special Resolution
	Independent Director of the Company	
5.	Approve appointment of Ms. Medha Joshi as an Independent	Special Resolution
	Director of the Company	
6.	Approve appointment of Mr. Rajesh Dalal as an Independent	Special Resolution
	Director of the Company	
7.	Approve appointment of Ms. Simi Thapar as an Independent	Special Resolution
	Director of the Company	
8.	Ratification of remuneration of Cost Auditors	Ordinary Resolution

Speaker shareholders were provided facility through VC and Audio-Visual means, to put forth their queries, comments and views.

Few shareholders put forth their queries and views which were responded by the Managing Director.

Managing Director then thanked all the shareholders for attending the meeting and for continued support to the Company. He requested the Company Secretary to make necessary announcements with regard to e-voting.

Company Secretary informed that the Company had provided remote e-voting facility through NSDL, to the shareholders to cast their votes electronically on all the resolutions set out in the Notice convening the meeting. Facility to vote through electronic voting system on all the items set out in the notice, was also made available at the meeting for those shareholders who had not cast their votes through remote e-voting before the meeting.

He further stated that Company had appointed Mr. Alwyn D'Souza, Practising Company Secretary, as Scrutiniser for the purpose of scrutinising the process of remote e-voting held prior and e-voting during the AGM. The results of the remote e-voting and e-voting at the 45<sup>th</sup> AGM, together with the Report of the Scrutinizers thereon, will be disclosed to the Stock Exchanges and will be displayed on the website of the Company within two working days.

## For Ajanta Pharma Ltd.

Gaurang Shah Sr. VP – Legal and Company Secretary

Date: 18.07.2024